111 Capital’s Exact Sciences EXAS Stock Holding History

111 Capital’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,921	Closed	-$580K	–	540
2025 Q2	$580K	Buy	+10,921	New	+$555K	0.1%	225

Other funds holding EXAS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

111 Capital's EXAS Position: Q3 2025 in Review

111 Capital sold out of Exact Sciences (EXAS) in Q3 2025, closing a stake of 10,921 shares — an estimated $580K sold.

111 Capital first reported a position in EXAS in Q2 2025 and held it in 1 quarter. The position peaked at $580K in Q2 2025. 567 funds tracked by Wall St. Rank hold EXAS as of Q3 2025.

111 Capital reported no remaining Exact Sciences position as of Q3 2025 after selling out during the quarter.
111 Capital sold 10,921 Exact Sciences shares in Q3 2025, an estimated $580K.
111 Capital first reported a position in Exact Sciences in Q2 2025 and held it in 1 quarter.
111 Capital's Exact Sciences position peaked at $580K in Q2 2025.
567 funds tracked by Wall St. Rank held Exact Sciences as of Q3 2025.

Based on 111 Capital's 13F filing for Q3 2025, filed 12 Nov 2025.